CD274 and neoplasm: The median [18F]-BMS-986192 and [89Zr]-nivolumab SUVpeak was higher for lesions with ≥50% tumor PD-L1 than for lesions with <50% expression (8.2 vs. 2.9, p = 0.018); and aggregates of PD-1 positive tumor-infiltrating immune cells (7.0 vs. 2.7, p = 0.03) (38)..